Antibody-drug conjugates(ADC)combine the targeting ability of monoclonal antibodies and the potent cytotoxicity of small molecule substances,becoming a research focus in the current biopharmaceutical field.Although various ADCs have been marketed globally,challenges still exist in formulation and stability.This review outlines the key points and difficulties in ADC formulation development and clinical application from the perspectives of antibody,linker,and small molecule substance selection for ADC,and proposes a stability study plan during ADC use,aiming to provide references for the future ADC development.
NETL
NSTL
万方数据
